Humacyte, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

bluebird bio, Inc.

MaxCyte, Inc.

uniQure NV

Humacyte, Inc.

Precigen, Inc.

Voyager Therapeutics, Inc.

Terns Pharmaceuticals, Inc.

Aura Biosciences, Inc.

Aldeyra Therapeutics, Inc.

Lyell Immunopharma, Inc.

Renovaro, Inc.

Why is Humacyte, Inc. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 16.15% and Operating profit at -423.48% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -13.82

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -69.16%, its profits have fallen by -16.9%

Below par performance in long term as well as near term

Along with generating -69.16% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Humacyte, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Humacyte, Inc.

-69.41%

-0.69

118.79%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.15%

EBIT Growth (5y)

-423.48%

EBIT to Interest (avg)

-13.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.18

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

55.91%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

11.15

EV to EBIT

-3.68

EV to EBITDA

-3.93

EV to Capital Employed

9.62

EV to Sales

408.13

PEG Ratio

Dividend Yield

ROCE (Latest)

-261.68%

ROE (Latest)

-333.22%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

NET SALES(9M)

At USD 0.82 MM has Grown at inf%

NET PROFIT(HY)

Higher at USD -59.34 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.39 times

DEBTORS TURNOVER RATIO(HY)

Highest at 4.15 times

-7What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -104.5 MM

INTEREST(9M)

At USD 8.05 MM has Grown at 32.93%

RAW MATERIAL COST(Y)

Grown by 58,870% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 1,126.16 %

Here's what is working for Humacyte, Inc.

Net Sales

At USD 0.82 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Net Profit

Higher at USD -59.34 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Inventory Turnover Ratio

Highest at 1.39 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 4.15 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at USD 1.86 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Humacyte, Inc.

Operating Cash Flow

Lowest at USD -104.5 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest

At USD 8.05 MM has Grown at 32.93%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio

Highest at 1,126.16 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 58,870% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales